J
Julie M. Vose
Researcher at University of Nebraska Medical Center
Publications - 569
Citations - 51589
Julie M. Vose is an academic researcher from University of Nebraska Medical Center. The author has contributed to research in topics: Transplantation & Lymphoma. The author has an hindex of 97, co-authored 541 publications receiving 46915 citations. Previous affiliations of Julie M. Vose include Memorial Hospital of South Bend.
Papers
More filters
Journal ArticleDOI
Central nervous system involvement in patients with diffuse aggressive non-Hodgkin's lymphoma.
TL;DR: Factors significantly associated with a greater likelihood of CNS relapse were age less than 60 years and epidural disease and tumor histology.
Journal ArticleDOI
International Peripheral T-Cell Lymphoma (PTCL) Clinical and Pathologic Review Project: Poor Outcome by Prognostic Indices and Lack of Efficacy with Anthracyclines.
TL;DR: A multivariate analysis of the two most common types, PTCL-unspecified and angioimmunoblastic, demonstrated the following factors to predict poor OS: poor performance status, age > 60 years, platelets < 150K, and factors associated with worse FFS.
Journal Article
Outpatient Treatment with 131I-Anti-B1 Antibody: Radiation Exposure to Family Members
Frank J. Rutar,Samuel C. Augustine,David Colcher,Jeffry A. Siegel,David A. Jacobson,Margaret A. Tempero,Valorie J. Dukat,Maribeth Hohenstein,Lisa S. Gobar,Julie M. Vose +9 more
TL;DR: Therapy with (131)I-anti-B1 antibody can be conducted on an outpatient basis using the established recommended protocol and doses to other individuals will be below the 5-mSv (500 mrem) limit.
Journal ArticleDOI
R-CHOP versus dose-adjusted R-EPOCH in frontline management of primary mediastinal B-cell lymphoma: a multi-centre analysis
Nirav N. Shah,Aniko Szabo,Scott F. Huntington,Narendranath Epperla,Nishitha Reddy,Siddhartha Ganguly,Julie M. Vose,Cynthia Obiozor,Fahad Faruqi,Alexandra E. Kovach,Luciano J. Costa,Ana C. Xavier,Ryan Okal,Abraham S. Kanate,Nilanjan Ghosh,Mohamed A. Kharfan-Dabaja,Lauren E. Strelec,Mehdi Hamadani,Timothy S. Fenske,Oscar Calzada,Jonathon B. Cohen,Julio C. Chavez,Jakub Svoboda +22 more
TL;DR: A retrospective, multicentre analysis of patients aged ≥18 years with PMBCL since January 2011, which represents the largest series comparing outcomes of R‐CHOP to DA‐R‐EPOCH forPMBCL.
Journal ArticleDOI
Brentuximab vedotin in combination with nivolumab in relapsed or refractory Hodgkin lymphoma: 3-year study results
Ranjana H. Advani,Alison J. Moskowitz,Nancy L. Bartlett,Julie M. Vose,Radhakrishnan Ramchandren,Tatyana Feldman,Ann S. LaCasce,Beth A. Christian,Stephen M. Ansell,Craig H. Moskowitz,Lisa Brown,Chiyu Zhang,David R. Taft,Sahar Ansari,Mariana Sacchi,Linda Ho,Alex F. Herrera +16 more
TL;DR: In this paper, a phase 1-2 study evaluated brentuximab vedotin (BV) combined with nivolumab (Nivo) as first salvage therapy in patients with relapsed/refractory (r/r) classical Hodgkin lymphoma (cHL).